EN DE
Watch Cinclus Pharma for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Cinclus Pharma (CINPHA) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Cinclus Pharma stock SEK 7.73, price SEK 12.08, that is 36.0% below the price, quality 41 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SE · ISIN SE0020388577

CP Cinclus Pharma logo Thin data Nov 3, 2026

Cinclus Pharma

CINPHA · ST
Very expensive, weak quality

Our calculation puts a fair price 36% below what the stock costs today.

Quality 41/100
Expensive Growth (revenue 3y +75.8 %/yr in SEK)
Fair value kr 7.73 · Strongly overvalued (−36.0%)
Negative free cash flow
Trails peers (1/7)
Narrow moat 10/100 · thin data
Thin data
Watch Cinclus Pharma for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 35.00 kr 9.43 Fair Value kr 7.73 Jun 2024 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.

How to read this chart

29‑month range kr 9.43 – kr 35.00 · fair‑value band kr 5.10 – kr 9.66 · the kr 12.08 price screens above the kr 7.73 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.

Follow Cinclus Pharma in your weekly email

Every Wednesday you see whether Cinclus Pharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China.

Show moreShow less

The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease.

It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori. Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden.

Stock analysis

Cinclus Pharma (CINPHA) currently trades at kr 12.08, while our model-based Fair Value estimate is kr 7.73, 36% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 92/100, which puts the data coverage at low.

Scenario range: kr 5.10 (bear) to kr 9.66 (bull), the price of kr 12.08 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Cinclus Pharma reported revenue of 57.5M SEK in FY2025 versus 10.6M SEK in FY2022, a compound +75.8%/yr. Reported net income was −184M SEK in FY2025.

Key figures

Market cap 562M SEK (≈ $56.9M) Micro · P/S ratio 15.8 · EPS (TTM) kr −5.78 · Return on equity −79.9% · Return on assets (EBIT) −97.5% (4-year average) · Operating margin −5,381% · Revenue (TTM) 35.2M SEK · Revenue growth (YoY) −94.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 38% below its 52-week high and 12% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −36%, CINPHA screens richer than that median.

Fair Value models

Bear kr 5.10 Fair Value kr 7.73 Bull kr 9.66
Price kr 12.08 · Downside -36.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) kr 5.10 kr 7.73 kr 9.66 52
All 1 models by family
Asset-Based
NCAV (Graham) kr 5.10 kr 7.73 kr 9.66 52

Open the full fair value analysis →

Quality Score breakdown

Overall quality 41/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 75
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 75
Debt, balance sheet and risk of trouble
Investment 33
Does it invest with discipline instead of growing at any price?
Low Volatility 67
How calm the share price moves, does not count
Price momentum 34
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 7
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+1,154.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+75.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,993.5% (2022) → −344.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

CINPHA screens overvalued: fair value 36% below the price. Compare with Merck KGaA →

Compare Cinclus Pharma with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 41 · Bottom 25%
Fair Value upside −36.0% · Below median
Profitability
Return on assets −33.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −94.8% · Bottom 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 1.52× · Cheaper than median
P/S (12 months) 15.98× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $79.40 $111.63 +41% vs CINPHA
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥50.43 ¥55.21 +9% vs CINPHA
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,860 ₹1,947 +5% vs CINPHA
Haleon plc HLN $9.14 $8.61 −6% vs CINPHA
Merck KGaA MRK €148.75 €109.18 −27% vs CINPHA
Galderma Group GALD CHF 191.75 CHF 109.86 −43% vs CINPHA
Takeda Pharmaceutical Company TAK $21.02 $11.31 −46% vs CINPHA
Teva Pharmaceutical Industries Limited TEVA $42.61 $20.74 −51% vs CINPHA
Sandoz Group SDZ CHF 83.78 CHF 39.70 −53% vs CINPHA
Divi's Laboratories Limited DIVISLAB ₹10,321 ₹1,567 −85% vs CINPHA

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cinclus Pharma: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Cinclus Pharma Fair Value". https://www.fairvalue-calculator.com/stock/CINPHA

Frequently asked questions

Is Cinclus Pharma (CINPHA) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of kr 7.73 versus a price of kr 12.08, about 36% lower (overvalued).
What is the fair value of CINPHA?
Our model-based fair value for Cinclus Pharma is kr 7.73 (as of Nov 3, 2026), built from audited fundamentals. The current price: kr 12.08.
What is the quality score of CINPHA?
Cinclus Pharma has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cinclus Pharma (CINPHA)?
Our model-based price target is the fair value of kr 7.73 (as of Nov 3, 2026) from 1 valuation models. Cautious scenario kr 5.10, optimistic scenario kr 9.66. It is a calculation from audited fundamentals, not an analyst target.
What is the Cinclus Pharma stock forecast for 2026?
Our models put fair value at kr 7.73, about 36% lower versus a price of kr 12.08 (overvalued). Cautious scenario kr 5.10, optimistic scenario kr 9.66. The calculation is refreshed regularly with new filings.
What is the revenue of Cinclus Pharma (CINPHA)?
Cinclus Pharma reported trailing-twelve-month revenue of about 35.2M SEK (latest available figure, as of Nov 3, 2026).
What is the intrinsic value of Cinclus Pharma (CINPHA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cinclus Pharma it is kr 7.73 per share (as of Nov 3, 2026), against a price of kr 12.08. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Cinclus Pharma stock overvalued or undervalued in 2026?
As of Nov 3, 2026, CINPHA trades above its calculated fair value: price kr 12.08, fair value kr 7.73, a gap of about −36% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CINPHA?
No. The price is what the market pays today (kr 12.08); the fair value is what the company's own numbers justify (kr 7.73). For Cinclus Pharma the two are kr 4.35 per share apart. That gap is exactly why we show both numbers side by side.
How much is Cinclus Pharma worth?
The market values Cinclus Pharma at about 562M SEK (market capitalisation, as of Nov 3, 2026). Per share that is kr 12.08; our models calculate a fair value of kr 7.73 per share.
What do the bullish and bearish scenarios say about CINPHA?
Our models span a range for Cinclus Pharma: cautious scenario kr 5.10, base kr 7.73, optimistic kr 9.66 per share (as of Nov 3, 2026, price kr 12.08). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Cinclus Pharma (CINPHA)?
Balance-sheet figures for Cinclus Pharma (as of Nov 3, 2026): return on equity −79.9%. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is CINPHA from its 52-week high?
Cinclus Pharma trades at kr 12.08, about 38% below its 52-week high of kr 19.46 and 12% above the low of kr 10.82 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of kr 7.73 is for.
Which stocks are comparable to Cinclus Pharma?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cinclus Pharma stock attractive at the current price?
The data as of Nov 3, 2026: price kr 12.08, calculated fair value kr 7.73 (−36%), Quality Score 41/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CINPHA calculated?
We run Cinclus Pharma through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of kr 7.73 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Cinclus Pharma itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cinclus Pharma (CINPHA)?
The closing price on Nov 6, 2026 was kr 12.08. Our model-based fair value is kr 7.73, about 36% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cinclus Pharma right now?
The price sits above even our optimistic bull case (kr 9.66). The favourable scenario is already priced in. Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (kr 5.10 to kr 9.66) leaves room in how you read the outcome.

Key figures of Cinclus Pharma

How large is the market capitalisation of Cinclus Pharma (CINPHA)?
The market capitalisation of Cinclus Pharma is 562M SEK (≈ $56.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cinclus Pharma (CINPHA)?
The price-to-sales ratio of Cinclus Pharma is 15.8 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Cinclus Pharma (CINPHA)?
Earnings per share at Cinclus Pharma are kr −5.78. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Cinclus Pharma (CINPHA)?
The return on equity (ROE) of Cinclus Pharma is −79.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cinclus Pharma (CINPHA)?
On an EBIT basis the return on assets of Cinclus Pharma is −97.5% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cinclus Pharma (CINPHA)?
The operating margin of Cinclus Pharma is −5,381% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Cinclus Pharma (CINPHA)?
Revenue at Cinclus Pharma is growing −94.8% versus a year earlier (3y avg +75.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Cinclus Pharma (CINPHA) generate?
The free cash flow of Cinclus Pharma is −75.8M SEK (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Cinclus Pharma (CINPHA) carry?
The net debt of Cinclus Pharma is 42.4M SEK (fiscal year 2023). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Cinclus Pharma in the live analysis

One click puts Cinclus Pharma on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.